Navigation Links
Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association

Field Moving Toward Genotype-Guided Psychotropic Therapy

SAN FRANCISCO, May 21 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., President of Genomas, and Director of Genetics Research at Hartford Hospital and Simon Kung, M.D., Assistant Professor of Psychiatry at the Mayo Clinic will co-chair a symposium, "Emerging Clinical Applications of Genotype-Guided Psychotropics for Depressive Disorders," at the annual meeting of the American Psychiatric Association.

"Genotyping is at a point where it could be used to help guide therapeutic choices," said the Mayo Clinic's Dr. Kung. "It's fitting that Mayo Clinic, Genomas and Institute of Living/Hartford Hospital partnered on today's symposium since these institutions are among the true innovators in delivering personalized medicine to patients."

Papers presented at today's symposium were:

Greater Utilization of Psychiatric Services is Associated with Pharmacogenetic Variation and Metabolism Deficiencies

Gualberto Ruano, M.D., Ph.D., and John W. Goethe, M.D.

Genomas Inc. and Institute of Living/Hartford Hospital, Hartford, CT

Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic Mood Disorders Unit

Simon Kung, M.D.

Mayo Clinic, Rochester, MN

Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices

Jinger G. Hoop, M.D., M.F.A.

Medical College of Wisconsin, Milwaukee, WI

The Serotonin Transporter Gene (SLC6A4): Understanding Variability and Enhancing the Clinical Utility of Genotyping

David Mrazek, M.D.

Mayo Clinic, Rochester, MN

Dr. Ruano presented results from a study that showed a significant link between certain genetic variations and length of stay and re-hospitalization rates for patients treated for major depressive disorder (MDD). Data were obtained from the DNA of 150 psychiatric in-patients being treated for MDD with antidepressant and atypical antipsychotic medications at the Institute of Living.

"These genetic variations may contribute to a reduction in efficacy or an increase in side effects of medications," said Dr. Ruano.


Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company is developing and testing revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit for more information.

SOURCE Genomas
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
2. Genomas to Present at Life Sciences & Healthcare Venture Summit
3. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
4. Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy
5. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
6. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
7. The Hamner Institutes Announce Partnership With China Medical City
8. New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
9. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
10. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
11. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):